Osteocis (Sodium Oxidronate)

Osteocis is a bisphosphonate indicated for disorders affecting the skeletal system where bone resorption is increased.

• Osteoporosis: improves bone mineral density and reduces fracture risk.
• Paget's disease of bone: normalises abnormal bone remodeling.
• Hypercalcaemia of malignancy: lowers elevated serum calcium levels.
• Bone metastases associated with solid tumours: helps control skeletal‑related events.
• Osteogenesis imperfecta: increases bone strength in selected cases.
• Steroid‑induced osteoporosis: mitigates bone loss due to long‑term glucocorticoid therapy.

• Sodium ​​​​​​​ ​   ​  ​  ​  ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​​​​  inhibits osteoclast‑mediated bone resorption by binding to hydroxy‑apatite crystals and disrupting the mevalonate pathway, thereby reducing osteoclast activity and bone turnover.

Sodium Oxidronate may cause a range of adverse reactions, most of which are dose‑dependent and related to its action on bone metabolism.

Common Side Effects

• Flu‑like symptoms: fever, chills, myalgia.
• Musculoskeletal pain: bone, joint or muscle discomfort.
• Nausea or vomiting.
• Transient elevation of serum creatinine.
• Injection site reactions: erythema or swelling.

Serious or Rare Side Effects

• Osteonecrosis of the jaw (ONJ).
• Atypical femoral fractures.
• Severe renal impairment.
• Hypocalcaemia.
• Acute phase reactions with severe fever.
• Anaphylactic or severe allergic reactions.

• Before                              ​   ​        ​    ​          ​      ​ ​       ​               ​        ​ ​   “         …   …  …  “    “  …  …  “  …  “  “  …  …  …  “  … …  “  …  “  </     "    “  …  “ bullet   “ …  “ … … …  “ …  “ …  ...